Applied UV, Inc. Stock Price, News & Analysis

Applied UV (AUVI) reports alarming increases in hospital infections, with a 60% rise in C. auris and a 13% increase in MRSA infections according to CDC data. The company emphasizes the effectiveness of its Airocide® Air Purification System in combating these pathogens. A clinical trial at Mt. Sinai Medical Center is underway to validate its LumiCide Surface and Drain systems, expected to conclude by year-end. Applied UV's innovations address serious healthcare-associated infections, which affect approximately 1.4 million patients annually in the U.S., contributing to a staggering $9.8 billion in increased healthcare costs.

Applied UV, Inc. (AUVI) announced a cash dividend of $0.21875 per share for its 10.5% Series A Cumulative Perpetual Preferred Stock (AUVIP). This dividend will be paid on or about October 17, 2022, to shareholders on record as of the close of business on October 3, 2022. The company specializes in pathogen elimination technologies, applying UVC light for disinfection in various high-traffic areas.

Applied UV, Inc. (AUVI) announced that its pathogen elimination technology, Airocide® and Lumicide, effectively addresses CDC recommendations for disinfecting against Monkeypox and other orthopoxviruses. The CDC highlighted that Monkeypox is sensitive to UV light, creating market opportunities for Applied UV. CEO John F. Andrews emphasized the company's unique position in capturing this emerging market, aided by a growing client base including Whole Foods and the Boston Red Sox. Airocide, developed for NASA, uses advanced technology to kill airborne pathogens, offering solutions across various sectors.

Applied UV (NASDAQ: AUVI) has announced a significant domestic production order valued at approximately $1.5 million for furniture and mirrors for a luxury resort in Orlando, Florida. This order validates the company's strategy of enhancing domestic manufacturing capabilities, which aims to mitigate supply chain risks. The company expects to generate up to $8 million in incremental sales from projects currently being expedited through its new facility. The partnership with hotel operators highlights the value of their air purification technology.

Applied UV, Inc. (NASDAQ: AUVI) has secured a significant order valued at $625,000 from the St. Joseph, Missouri School District for its Airocide™ and Scientific Air™ S400 air purification systems. This order represents a pivotal step into the K-12 education market, serving over 10,600 students across 24 schools. The company anticipates delivering these units in the second half of 2022. Applied UV is also engaging in a multi-million-dollar procurement process in Washington, with $300,000 in submissions already made.

Applied UV has announced a cash dividend of $0.21875 per share to holders of its 10.5% Series A Cumulative Perpetual Preferred Stock (NASDAQ: AUVIP). The dividend will be paid on or about September 15, 2022, to shareholders on record as of the close of business on September 2, 2022. This dividend reflects the company's commitment to delivering value to its investors while maintaining a focus on advancing pathogen elimination technology across various markets.

Applied UV, Inc. (NasdaqCM: AUVI) reported second-quarter 2022 revenues of $5.9 million, a 213.5% increase from $1.9 million in Q2 2021. Growth was driven by its Disinfection and Hospitality segments due to strategic acquisitions and order fulfillment. Gross profit rose 144.5% to $1.3 million, but gross profit margin decreased to 22.1%. SG&A expenses increased $1.3 million to $4.0 million, leading to a net loss of $2.9 million. The company aims to optimize cost efficiencies as it integrates new acquisitions.

Applied UV, Inc. (AUVI) announced a lawsuit against Aeroclean Technologies, Inc. (AERC), seeking $20 million in damages for trademark infringement and unfair competition. The lawsuit, filed by its subsidiary Sterilumen, claims Aeroclean improperly used a trademark associated with Sterilumen's air purification products, causing market confusion. CEO John F. Andrews emphasized the importance of protecting their brand and the investments made in their patented technologies. The case is lodged in the U.S. District Court for the Southern District of New York.

Applied UV, Inc. (NASDAQ: AUVI), a pathogen elimination technology company, will host an investor conference call and live webcast on August 16, 2022, at 9:00 am ET to discuss its second quarter 2022 financial results. Results will be released on August 15 after market close. Investors can access the call via the company's website or by phone at +1-888-506-0062 (domestic) or +1-973-528-0011 (international) with passcode 660050. A replay will be available for one week following the call.